Compare BBAR & MMED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BBAR | MMED |
|---|---|---|
| Founded | 1886 | 1983 |
| Country | Argentina | United States |
| Employees | N/A | 2800 |
| Industry | Commercial Banks | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 4.3B |
| IPO Year | 1997 | 2026 |
| Metric | BBAR | MMED |
|---|---|---|
| Price | $18.86 | $16.83 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 10 |
| Target Price | $17.00 | ★ $22.56 |
| AVG Volume (30 Days) | 497.5K | ★ 1.2M |
| Earning Date | 05-20-2026 | 06-03-2026 |
| Dividend Yield | ★ 2.04% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.32 | $15.99 |
| Revenue Next Year | $11.04 | $10.00 |
| P/E Ratio | $26.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.76 | $10.65 |
| 52 Week High | $22.47 | $17.86 |
| Indicator | BBAR | MMED |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 63.33 |
| Support Level | $18.59 | $14.70 |
| Resistance Level | $19.21 | N/A |
| Average True Range (ATR) | 1.09 | 0.90 |
| MACD | -0.21 | 0.04 |
| Stochastic Oscillator | 4.53 | 73.31 |
Banco BBVA Argentina SA is a banking services provider in Argentina. It provides financial assistance to large corporations, small and medium-sized companies, as well as individuals. It bank provides services through retail, corporate, investment banking, and Small and medium-sized companies divisions. Through the retail banking segment, it provides banking products and services to individuals, corporate banking deals with services to corporates, and the small and medium-sized companies segment focuses on foreign trade, agricultural business, and digital products.
Minimed Group Inc is a scaled medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. It serves PWD who require intensive insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform of simple and clinically effective solutions for PWD requiring insulin therapy includes Automated Insulin Delivery (AID) Systems and Smart Multiple Daily Injection (MDI) Systems. It derives revenue from the sale of products focused on diabetes management, including insulin pumps, continuous glucose monitoring systems and sensors, and smart insulin pens. Geographically, it operates in the USA and the Rest of World, with the majority of revenue derived from the Rest of World.